NCT02206295View on ClinicalTrials.gov

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

PHASE1CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Bioequivalence

Interventions

DRUG

selexipag

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Actelion

INDUSTRY

NCT02206295 - Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg | Biotech Hunter | Biotech Hunter